Lay Summary
Ritivixibat (A3907) Phase 2 Clinical Trial Results
Safety results for the Phase 2 ritivixibat study (A3907) for PSC have been released.
Read MorePiSCATIN study reaches full recruitment milestone
The PiSCATIN study has enrolled 570 participants, moving us closer to potential PSC treatments.
Read MorePSC Support Signs Landmark European Declaration to Accelerate Rare Disease Innovation
PSC Support joins European leaders to advocate for a cohesive ecosystem in rare disease care.
Read MoreFebruary 2026 Research Roundup
A month of leadership growth, breakthrough research, and new milestones in clinical care.
Read MoreDriving Global Change Through the Patient Voice
New global survey results reveal the significant impact of itch on life with PSC.
Read MoreEpstein-Barr Virus and PSC
New research explores a potential link between Epstein-Barr virus and primary sclerosing cholangitis.
Read MoreMajor Milestone Reached in PSC Cancer Risk Study
100 samples collected: DNA methylation study advances early cancer detection in PSC.
Read MoreProgress Update: Characterising Genetic Changes in Bile Ducts
PSC research on genetic changes in bile ducts is now in its key analytical phase to unlock understanding.
Read MoreMolecular Signatures Identified to Predict Primary Sclerosing Cholangitis Progression and Cancer Risk
New blood-based markers could help predict primary sclerosing cholangitis progression and cancer risk.
Read MorePSC-IBD Bowel Cancer Risk Study Shows Promising Findings
New PSC-IBD research from Dr Chandni Radia suggests bowel cancer risk may be lower than previously thought, helping us build evidence to tailor future colonoscopy guidelines.
Read More